Endocyte, Inc. has been awarded a patent from the United States Patent and Trademark Office covering vitamin receptor binding anti-cancer agents. The patent, entitled “Vitamin Receptor Binding Drug Delivery Conjugates” (U.S. Patent No. 7,601,332), covers novel conjugation linkages and anti-cancer agents, including Endocyte’s EC145, which is currently in development as a potential treatment for ovarian and non-small cell lung cancers.
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
1201 Maryland Avenue SW, Suite 900, Washington, DC, 20024 ・ 202-962-9200
© BIO 2020 All Rights Reserved